Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Alembic Pharmaceuticals on Monday said the US health regulator has made five observations after inspection at its center at Karkhadi, Gujarat.
“The United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals” New Injectable Facility (F-3) located at Karkhadi from January 29-February 5, 2021.
This was a scheduled inspection and at the close of the inspection, the USFDA issued a form 483 with 5 observations, the company said in a regulatory filing.
According to the USFDA, a Form 483 is issued to a firm”s management at the conclusion of an inspection when an investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. It informs the company”s management of objectionable conditions.
Alembic Pharma said none of those observations were associated with data integrity and were procedural in nature.
“The company is preparing the answer to the observations, which will be submitted to USFDA shortly,” the company said.
Shares of Alembic Pharmaceuticals were trading 0.44 percent higher at Rs 935.95 apiece on BSE.
